Lipoprotein(a), or Lp(a), is a protein that transports cholesterol in the blood. High levels of Lp(a) in the blood can increase the likelihood of plaques or blood clots forming in the arteries. As ...

Lipoprotein(a) is well established as a risk factor for cardiovascular disease, but patients rarely get tested for it. Now, an alliance between Novartis and genetic testing specialist 23andMe is ...

Novartis has turned to Ionis for another cardiovascular disease drug, putting $60 million down for a follow-up to lipoprotein(a)-targeting drug pelacarsen, which is now in phase 3 testing.

Zerlasiran, a siRNA therapy designed to treat atherosclerotic cardiovascular disease by “silencing” the LPA gene, was shown to produce a placebo-adjusted reduction from baseline lipoprotein A ...